Media OutReach
Hong Kong Genome Institute and Global Leaders Co-organise Landmark Healthcare Event “International Genomic Medicine Symposium”
Convening Experts to Promote Hong Kong and Advance Medical Innovation
HONG KONG SAR – Media OutReach Newswire – 25 June 2025 – Genomic medicine is one of the most promising fields in today’s healthcare landscape, enabling precise diagnoses, personalised treatment plans, and breakthroughs in drug development that bring new hope to patients around the world. The Hong Kong Genome Institute (HKGI) will join forces with world-renowned authorities to host the International Genomic Medicine Symposium (Symposium) on 17 November 2025 (Monday). This landmark event will highlight Hong Kong’s unique strengths in fostering exchange and cooperation with experts worldwide in medical research and innovation, and accelerate the application of genomic medicine to pave the way for a healthier future for all.
The Symposium marks HKGI’s first collaboration with Rare Diseases International (RDI) and The Lancet Commission on Rare Diseases (LCRD), which is jointly led by RDI and The Lancet, the world’s most influential medical journal. The event will welcome local and international genomics leaders from over 20 countries and regions, including clinicians, scientists, and researchers from Mainland China, Europe, North and South America, and Australia.
Distinguished speakers at the Symposium will focus on key global topics such as clinical genetics, rare diseases, genomic medicine, AI, data sharing, as well as ethical and legal matters involved, facilitating in-depth discussions on the latest groundbreaking research and clinical insights. Specifically, thematic sessions will be dedicated to experience sharing by experts from Mainland China and Hong Kong. By showcasing case studies from the Hong Kong Genome Project, these exchanges will help demonstrate practical applications of personalised medicine in managing common disorders such as cardiomyopathy and kidney disease. Developments in rare diseases in Mainland China and drug development opportunities in the Guangdong-Hong Kong-Macao Greater Bay Area will also be covered, opening doors of opportunity for regional collaboration and innovation.
Dr Lo Su-vui, Chief Executive Officer of HKGI said, “With the strong support from the Health Bureau of the Hong Kong SAR Government, HKGI has been working closely with the Department of Health, Hospital Authority, medical schools of local universities and various stakeholders to accelerate the development of genomic medicine in Hong Kong. In just a few years, the Institute has achieved significant milestones in medical research, clinical applications, and international collaborations. We have successfully recruited over 47,000 participants for the Hong Kong Genome Project, continuously expanding our genome database featuring the Southern Chinese population. We have also accumulated clinical application cases and established synergistic collaborative research platforms. These achievements highlight Hong Kong’s strong capabilities and advantages in genomic medicine, laying a solid foundation for further collaboration with internationally recognised authorities.”
Dr Lo continued, “We are greatly honoured to partner with RDI and LCRD to organise this prestigious global event. Genomic medicine is the future of medicine with wide-ranging applications, spanning from common to rare diseases, from clinical diagnosis and personalised treatment to disease prevention and health management. This Symposium will undoubtedly serve as a critical platform for healthcare experts, academics, and researchers from around the world to exchange knowledge, fostering collaboration, and driving medical innovation, ultimately bringing immense benefits to patients in Hong Kong, Asia and beyond.”
The one-day Symposium is expected to attract nearly 300 industry professionals. Following the Symposium, the LCRD will hold its annual meeting in Hong Kong on 18-19 November to further discuss insights and deepen cross-regional collaboration. This will be the first time for the LCRD to host its annual meeting in Asia, highlighting Hong Kong’s distinctive position in leading international medical innovation.
For information about the Symposium programme and speakers, please refer to the appendix. For enquiries about the Symposium, please contact HKGI ([email protected]) or RDI-LCRD ([email protected]).
| Time | Programme | Speaker |
| 09:00 | Keynote | Prof Lo Chung-mau, BBS, JP Secretary for Health Hong Kong SAR Government, Hong Kong, China |
| 09:15 | Opening Ceremony | |
| Panel 1 | Session Chairperson: | Dr Ronald Lam, JP Director of Health Hong Kong SAR Government, Hong Kong, China |
| 09:30 | Developing Rare Disease Models in China: Service, Teaching and Research | Prof Zhang Shuyang President Peking Union Medical College Hospital, China |
| 10:00 | Unraveling Molecular Pathogeneses to Enhance Patient Care and Family Well-being | Prof Kym Boycott Co-Chair Lancet Commission on Rare Diseases Professor of Pediatrics University of Ottawa, Canada |
| 10:30 | Panel Discussion | |
| Panel 2 | Session Chairperson: | Dr Libby Lee, JP Under Secretary for Health Hong Kong SAR Government, Hong Kong, China |
| 11:15 | Insights into Rare Diseases: Focus on Inborn Errors of Metabolism |
Prof Roberto Giugliani Co-Chair Lancet Commission on Rare Diseases Professor of Genetics Federal University of Rio Grande do Sul, Brazil |
| 11:45 | Hong Kong Genome Project Case Sharing (1) – Unlocking the Genomics of Cardiomyopathy: A New Era in Heart Health | Dr Derek Lee Hong Kong College of Physicians – Hong Kong Genome Institute Scholar Hong Kong, China |
| 12:00 | Hong Kong Genome Project Case Sharing (2) – Precision Medicine in Nephrology | Dr Becky Ma Hong Kong Academy of Medicine – Hong Kong Genome Institute Scholar Hong Kong, China |
| 12:15 | Panel Discussion | |
| 12:30 | Lunch | |
| Panel 3 | Session Chairperson: | Prof Philip Chiu Dean of Medicine The Chinese University of Hong Kong, Hong Kong, China |
| 14:00 | Revolutionising Plasma DNA Analysis in Transforming Non-invasive Testing and Cancer Detection | Prof Dennis Lo, SBS, JP Vice-Chancellor and President The Chinese University of Hong Kong Board Member Hong Kong Genome Institute Hong Kong, China |
| 14:30 | Publishing at The Lancet | Dr Chloe Wilson Senior Medical Editor The Lancet |
| 15:00 | Panel Discussion | |
| Panel 4 | Session Chairperson: | Prof Lau Chak-sing, BBS, JP Vice-President & Pro-Vice-Chancellor (Health) Dean of Medicine The University of Hong Kong Board Member Hong Kong Genome Institute Hong Kong, China |
| 15:35 | AI in Action: The Journey from Clinical Record to Personalised Treatment |
Prof Gareth Baynam Medical Director Rare Care Centre Perth Children’s Hospital, Australia |
| 16:05 | Harnessing the Power of Electronic Healthcare Records in Scientific Research and Innovation in Genomic Medicine | Prof Yong Chen Professor of Biostatistics University of Pennsylvania, USA |
| 16:35 | Panel Discussion | |
| Panel 5 | Session Chairperson: | To be confirmed |
| 16:50 | The Health Rights of Children and Genomic Newborn Screening | Prof Bartha Knoppers Director Centre of Genomics and Policy McGill University, Canada |
| 17:20 | Hong Kong Genome Project: Advancing the Genomics Frontier |
Dr Brian Chung Chief Medical and Scientific Officer Hong Kong Genome Institute, Hong Kong, China |
| 17:40 | Genomics as a Catalyst for Drug Development in the Greater Bay Area |
Prof Aya El Helali Clinical Assistant Professor Department of Clinical Oncology, School of Clinical Medicine, The Li Ka Shing Faculty of Medicine of the University of Hong Kong, Hong Kong, China |
| 18:00 | Panel Discussion | |
| 18:15 | End of Symposium | |
Hong Kong Genome Institute
Website: www.hkgp.org
Email: [email protected]
Rare Disease International
Website: www.rarediseasesinternational.org
Email: [email protected]
Hashtag: #HongKongGenomeInstitute
The issuer is solely responsible for the content of this announcement.
About Hong Kong Genome Institute
The Hong Kong Genome Institute (HKGI), established and wholly owned by the Hong Kong SAR Government, commenced full operations in 2021. With the vision “to avail genomic medicine to all for better health and well-being” and supported by the Health Bureau, HKGI works in close collaboration with the Department of Health, Hospital Authority, medical schools of local universities and other stakeholders to accelerate the development of genomic medicine in Hong Kong along four strategic foci: integrate genomics into medicine, advance research, nurture talents and enhance public genomic literacy.
As the first step towards achieving its vision, HKGI launched the Hong Kong Genome Project (HKGP) in 2021 focusing on diseases and research cohorts that would benefit from whole genome sequencing. They include undiagnosed diseases, hereditary cancers and cases related to genomics and precision health. Being the city’s first large-scale genome sequencing project, HKGP serves as a catalyst to benefit patients and their families with more precise diagnosis and personalised treatment. It also aims to establish genome database of the local population, testing infrastructure and talent pool to address the healthcare needs of Hong Kong in the long run.
For more information, please visit 
https://hkgp.org/en.
About Rare Diseases International
Rare Diseases International (RDI) is the global alliance of people living with a rare disease of all nationalities across all rare diseases. RDI’s mission is to be a strong common voice on behalf of rare disease patients around the world, to advocate for rare diseases as an international public health priority and to represent its members and enhance their capacities. RDI has more than 120 member organizations from 50 countries, which in turn represent rare disease patient groups in more than 150 countries worldwide.
For more information, please visit https://www.rarediseasesinternational.org.
About Lancet Commission on Rare Diseases
The RDI-Lancet Commission on Rare Diseases (RDI-LCRD) is a new initiative dedicated to improving the lives of Persons Living with a Rare Disease (PLWRD) globally by generating evidence-informed recommendations that can be implemented in all countries. The RDI-LCRD, chaired by Dr Roberto Giugliani (Brazil) and Dr Kym Boycott (Canada) brings together 27 Commissioners from 6 continents with a broad range of expertise, perspectives and experience. The overarching goal of the RDI-LCRD is to use robust data to ignite global action that will amplify the voices of PLWRD and ensure that they are seen, heard, and cared for, no matter where they live.
For more information, please visit http://www.rarediseasescommission.org.
By fully eliminating all PFAS-containing additives from its portfolio by the end of 2024, allnex has become one of the first companies in the industry to demonstrate that high-performance coatings can be achieved without so-called “forever chemicals.” PFAS are increasingly questioned because they persist in the environment for long periods of time and pose health risks, although they remain legally permitted in many applications.
“We did not wait for regulation – we took responsibility,” said Rainer Blaha, Business VP additives. “The EU Product Safety Award validates our commitment to actively shaping product safety and sustainable chemistry, rather than simply meeting minimum standards.”
A Measurable Contribution to Product Safety
Through the transition to PFAS-free alternatives, allnex has enabled the production of approximately 18 million liters of PFAS-free paints and coatings in the EU, and 37 million liters globally. This significantly reduces exposure for professional users and end consumers, while preventing the release of persistent chemicals into the environment.
Having phased out PFAS containing additives, allnex now offers high performance alternatives developed in line with strict internal safety and sustainability criteria. allnex strictly followed safe-by-design principles, avoiding “regrettable substitutions” and prioritizing non-persistent, non-toxic raw materials.
A Benchmark for Industry-Wide Change
The jury of the EU Product Safety Award acknowledged allnex’s phase-out of PFAS-containing additives as a clear example of a proactive, forward-looking product safety initiative. At the same time, allnex supports its customers in preparing for future regulatory requirements and in meeting the criteria of ecolabels such as the EU Ecolabel, Nordic Swan, and Blue Angel.
“This award sends a strong signal to the entire industry,” added Rainer Blaha. “It proves that voluntary, forward-looking action is not only possible, but that it creates real value for people, the environment, and the market.”
The EU Product Safety Award is presented annually by the European Commission and honors companies whose innovative initiatives make an outstanding contribution to product safety.
For more information on the products, visit allnex product finder on allnex.com
For product related questions please reach out to [email protected]
Hashtag: #allnex
The issuer is solely responsible for the content of this announcement.
About allnex
allnex is a leading global manufacturer and solution provider of coating resins and additives for industrial and composite markets. With a 75-year heritage, over €2.2 billion in revenue and 4,000 employees worldwide, our focus is to create innovative chemistry for all nex>t generations, driven by the needs of our customers in a fast-changing world. We do this with sales, research and production network spanning 35 countries, a workforce representing over 50 nations with an all-in dedication to innovation, sustainability and reliable partnership.
allnex supports customers to enhance their product and service solutions with a wide range of chemistries and innovative products, including the sustainable ECOWISE™ offerings. As part of PTT Global Chemical (PTTGC), our main markets are Mobility & Transportation, Packaging & Consumer Goods and Construction & Infrastructure.
For more information, please visit 
https://allnex.com/en
Media OutReach
Columbia Asia Hospital Cheras Marks 15th Anniversary with Expansion, Wins MPRA 2025 Silver Award for Best Use of Content
Produced under the hospital’s flagship health education program, the episode was released on 26 June 2025 and featured SAHI host and social media influencer Dr Malar Santhi and ENT specialist Dr Hazmi Mohamed. It highlighted risks such as tinnitus, hearing loss and ear infections while promoting preventive habits like the 60-60 Rule (using headphones/earphones for no more than 60 minutes at a time at 60 per cent volume). Its conversational and empathetic format sparked exceptional engagement:
- 1.5 million views on TikTok
- 54,000+ likes and 1,000+ comments.
- 154,000 views and 4,000+ shares on Instagram
- 1.9 million views and more than 9,000 interactions on Facebook
- Over 65,000 forwards across all platforms
The public discussion was profound, with parents debating their children’s listening habits, youths admitting to using earbuds as social coping tools, and individuals with early hearing damage urging others to act early. “This Silver Award is more than just a recognition of content excellence, it reflects our commitment to educating the public and delivering healthcare that is accessible, modern, and deeply human,” said Columbia Asia (Region 1) Regional CEO Puan Engku Marina Engku Hatim. “As we celebrate 30 years in Malaysia and 15 years in Cheras, our mission remains unchanged: to be right here for our community, every step of the way,” she added.
The hospital previously earned Gold for Best Use of social media and Silver for Healthcare at last year’s MPRA Awards, marking consecutive years of strong industry recognition.
Since opening in February 2011, CAH Cheras has grown into one of the region’s most trusted neighborhood hospitals. Over the past 15 years, it has cared for more than 1.3 million patients, delivering accessible, modern, and community-focused healthcare.
The hospital’s COO Sean Yoong added: “The expansion marks a transformative chapter for Cheras. With more beds, more specialists, and more advanced services, we are preparing for the next decade of healthcare demands. This aligns perfectly with our culture of innovation, seen in initiatives like SAHI, which enable us to communicate health messages in meaningful ways.”
In response to rising healthcare demands in the Klang Valley, CAH Cheras has undergone a major expansion scheduled to launch officially in 2026. The development will increase the hospital’s capacity from 78 beds to 180 beds, expand its medical team to 80 consultants, and introduce new specialties such as Neurosurgery, Nephrology and Advanced Endoscopic Surgery.
The expansion spans 40,000 sq ft across two interconnected buildings, significantly improving patient flow, service capacity and the hospital’s readiness for complex cases.
As Columbia Asia Hospital Cheras approaches its 15th anniversary and prepares to launch its expanded facilities in 2026, the hospital reaffirms its dedication to the Cheras and Klang Valley communities.
“This award is just the spark,” said Puan Engku Marina. “The real story is what comes next, better facilities, more specialists, expanded capabilities and a deeper commitment to the 1.3 million patients who have trusted us. We step into 2026 with bigger and more connected than ever.”Hashtag: #ColumbiaAsiaHospitalCheras #RightHereForYou #MalaysiaPRAwards2025 #PRCA #HealthcareExcellence #TeamCheras #CommunityCare #HospitalCommunications #AwardWinningTeam #LebihLuas
https://www.columbiaasia.com/malaysia/hospitals/cheras/
https://my.linkedin.com/company/columbia-asia-malaysia
https://twitter.com/columbiaasia?lang=en
https://www.facebook.com/ColumbiaAsiaHospitalCheras
https://www.instagram.com/columbiaasia/?hl=en
https://www.tiktok.com/@columbiaasiamalaysia
The issuer is solely responsible for the content of this announcement.
About Columbia Asia Hospital Cheras
Columbia Asia Hospital Cheras is a private hospital located in Cheras Selatan, Selangor, near the Kuala Lumpur border. Since opening in 2011, the hospital has been providing healthcare services to communities across Cheras and surrounding areas, including Balakong, Seri Kembangan, Serdang, Putrajaya, Cyberjaya and Kajang. To meet the growing demand for quality private healthcare, the hospital is undergoing a major expansion with a new four-storey block and additional basement levels, scheduled for completion in 2026. The expansion will increase capacity from 78 to 180 beds and expand outpatient services to 37 clinics.
Columbia Asia Hospital Cheras offers a comprehensive range of medical specialties including Cardiology, Obstetrics & Gynecology, Pediatrics, Orthopedics, General Surgery, Internal Medicine, Ophthalmology, Urology and Radiology, supported by modern facilities such as a 24-hour Accident & Emergency Department, Catheterization Lab, 128-slice CT scanner and 1.5 Tesla MRI.
New specialties including Gyne-Oncology, Maternal-Fetal Medicine, Orthopedic Trauma, Breast & Endocrine Surgery and Pediatric Neurology will be introduced, alongside enhanced surgical, ICU, wellness screening and dialysis services. Through this expansion, the hospital reaffirms its commitment to delivering accessible, high-quality healthcare to families in Selangor and Kuala Lumpur.
About Columbia Asia
For 30 years, Columbia Asia Group of hospitals has been at the forefront of quality healthcare in the private healthcare industry. Established in 1996, it has evolved from its first hospital in Shah Alam to its latest in Penang, to date. As an international healthcare provider, its services span across 19 hospitals in the region; 13 in Malaysia, five in Indonesia, and one in Vietnam. Through the years, the company strategy has always been about making private healthcare accessible to all, hence its hospitals are strategically located in densely populated areas. Under the umbrella of private healthcare company, Asia OneHealthcare, the Columbia Asia group has expanded its reach to bring not just world-class, but also effective healthcare, closer to home.
Through the years, Columbia Asia’s emphasis has consistently been about early detection of diseases. This is carried out by way of advanced technology for precise diagnostics, resulting in minimally invasive procedures. To fulfil the typical healthcare needs of communities, Columbia Asia offers core disciplines such as obstetrics & gynecology, pediatrics, and general surgery. Today, it also provides tertiary healthcare addressing more complex fields of medicine such as neurosurgery, cardiac disease treatments, and integrated cancer care.
As it approaches a new decade, Columbia Asia continues to expand; adopting cutting-edge technology to meet the ever-increasing needs of today’s discerning customers. Upholding strict clinical governance, medical ethics and acknowledged by the Malaysian Society for Quality in Health, Columbia Asia continues to deliver excellent patient outcomes in a safe and trusted environment.
Columbia Asia. Right Here For You.
About Asia OneHealthcare
Asia OneHealthcare (A1Health) is a leading healthcare provider in the region, uniting 32 hospitals across Malaysia, Vietnam, and Indonesia under one brand. Formed by the integration of CAH Medical Centres (formerly Ramsay Sime Darby Health Care), Columbia Asia Hospitals, and five esteemed super-specialty hospitals including ALTY Orthopaedic Hospital, Beacon Hospital, CVSKL, Hospital Picaso, and Northern Heart Hospital Penang, we are setting new standards in medical excellence.
With 23 hospitals in Malaysia, 8 in Indonesia, and 1 in Vietnam, A1Health offers a comprehensive range of secondary to quaternary and super-specialty services. Our facilities, with over 4,000 beds, are dedicated to personalised care.
We leverage the collective expertise and advanced technologies of our network to provide the latest in healthcare, delivered by highly skilled professionals. Our mission is to achieve the best outcomes in the most accessible, effective, efficient, and caring environment. Upholding our tagline, “Right Here For You,” we are committed to offering compassionate, expert care to every patient.
Media OutReach
Sincere Healthcare Group and Landmark Medical Centre Unite to Strengthen Cross-Border Patient Care Between Singapore and Johor Bahru
Integration improves access and continuity of specialist care across Singapore–Malaysia border
SINGAPORE –
For patients, this integration translates into a more coordinated and reassuring healthcare experience — particularly for those who travel between Singapore and Johor Bahru for consultations, treatment, follow-up care or second opinions. It reflects a broader regional focus on enabling care closer to home while maintaining high clinical standards and specialist access.
Shared Medical Heritage, Aligned with Patient-Centred Care
Both Sincere and Landmark were founded by clinicians who believe that good medicine begins with ethics, compassion and respect for patients. Landmark’s clinical foundation was established by Dr Robert Luk Tai Kong and continues under the leadership of Dr Lucas Luk, Managing & Medical Director, who has guided the centre’s steady growth while preserving its patient-first ethos.
Sincere Healthcare Group was founded by Prof Ng Soon Chye, a pioneer in fertility medicine whose contributions helped shape Assisted Reproductive Technologies (ART) in the region. Today, Sincere has grown into a multi-centre healthcare group providing obstetrics and gynaecology, women’s and men’s health, fertility care, minimally invasive and robotic gynaecological surgery, and colorectal services.
“Landmark has always focused on specialised care delivered with personal attention and clinical integrity,” said Dr Lucas Luk. “Integrating with Sincere allows us to expand our specialist support while preserving what patients value most — trust, familiarity and continuity of care.”
Supporting Seamless Cross-Border Care
Cross-border healthcare has become increasingly relevant as patients seek timely access, specialist expertise and flexible care options. This integration strengthens a clear, coordinated care pathway between Singapore and Johor Bahru, aligning with broader healthcare strategies that encourage collaboration, efficiency and patient mobility across the region.
Landmark’s central location in Johor Bahru near the Woodlands entry point, combined with Sincere’s presence near Tuas, allows patients to move more easily between care settings. Services in obstetrics and gynaecology, fertility treatment, and women’s and men’s health are now better connected across the two networks.
“Our focus has always been on how patients experience care,” said Ms Koh Lee Lee, Group Chief Executive Officer of Sincere Healthcare Group. “This integration supports a more holistic and connected approach, allowing patients to receive appropriate care at the right place and time, across Singapore and Malaysia.”
Expanding Care While Preserving Trust
Importantly, Landmark Medical Centre will continue operating under its established name, care teams and clinical philosophy. Patients can expect the same familiar doctors and environment, now supported by a broader specialist network, shared clinical standards and enhanced collaboration within the Sincere group.
“Medicine should always be guided by what is right for patients,” said Prof Ng Soon Chye, Medical Chairman of Sincere Healthcare Group. “By working together, we can strengthen care pathways, share expertise and support better outcomes for the people who trust us with their health.”
Looking Ahead
The integration represents a meaningful step in building sustainable, patient-centred healthcare capacity across the Singapore–Malaysia corridor. Continued investment in medical programmes, technology and specialist collaboration will support long-term care needs while complementing national healthcare priorities focused on quality, access and continuity.
For patients, the message remains simple: more access, more expertise and the same commitment to compassionate, ethical care — now delivered through a more connected cross-border healthcare network.Hashtag: #sincerehealthcaregroup #landmarkmedicalcentre #crossborderhealthcare #womenshealth #menshealth #obgyn #gynaecology #singaporehealthcare #johorbahruhealthcare #SGhealthcare #JBhealthcare #SingaporeMalaysia #integratedcare #specialistcare #continuityofcare
https://www.sincerehealthcaregroup.com/
https://www.linkedin.com/company/sincere-healthcare-group/
https://www.facebook.com/sincerehealthcaregroup/
https://www.instagram.com/sincerehealthcaregroup/
https://www.tiktok.com/sincerehealthcaregroup
The issuer is solely responsible for the content of this announcement.
Sincere Healthcare Group Pte Ltd
Sincere Healthcare Group is a private healthcare network in Singapore and Malaysia specialising in obstetrics and gynaecology (O&G), reproductive medicine, fertility care, and advanced women’s and men’s health services. Its centres provide comprehensive programmes including IVF, andrology, prenatal care, diagnostics, minimally invasive surgery and women’s health screening. Supported by experienced specialists, modern laboratories and technology-enabled systems, Sincere serves local and international patients seeking ethical, evidence-based care. Its portfolio also includes colorectal conditions, endoscopy, colonoscopy and laparoscopic surgical services. Expanding its regional presence, Sincere has established a Patient Liaison Centre in Shanghai, China, to support patients seeking fertility consultations and coordinated cross-border care.
Landmark Medical Centre Sdn Bhd
Landmark Medical Centre is a well-established healthcare provider in Johor Bahru, founded in 2005 and recognised for its trusted legacy, strong clinical leadership, and commitment to patient-centred care. It offers multidisciplinary services with core strengths in women’s health, obstetrics and gynaecology, surgical care, and general health services. Guided by medical integrity and long-standing community relationships, Landmark continues to deliver quality medical care supported by experienced clinicians and modern clinical facilities.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism9 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking7 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn